Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT — Stella

Home/Advanced Prostate Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Advanced Prostate Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

Dana Farber Cancer Institute, Boston, Massachusetts

Brigham and Womens Hospital, Boston, Massachusetts

Key details

Phase

Early testing

Sponsor

Brigham and Women's Hospital

Collaborators

Blue Earth Diagnostics

Enrollment target

~30 participants

Started

February 2024

Primary completion

September 2026

Age range

18 Years and older

Sex

Male only

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.